Phase II Study of Gemcitabine and Erlotinib as Adjuvant Therapy for Patients with Resected Pancreatic Cancer (Q37812010)

23 August 2017

title

Phase II study of gemcitabine and erlotinib as adjuvant therapy for patients with resected pancreatic cancer (English)

1 reference

23 August 2017

Phase II Study of Gemcitabine and Erlotinib as Adjuvant Therapy for Patients with Resected Pancreatic Cancer (English)

1 reference

https://api.crossref.org/works/10.1245/S10434-010-1401-9

2 September 2024

1 reference

1 reference

David L Bartlett

1 reference

23 August 2017

Herbert J Zeh

1 reference

23 August 2017

Steven J. Hughes

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21104328

2 September 2024

Alyssa Krasinkas

1 reference

23 August 2017

Nathan Bahary

1 reference

23 August 2017

Philip Q. Bao

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21104328

2 September 2024

Ramesh K. Ramanathan

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21104328

2 September 2024

Barry C. Lembersky

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21104328

2 September 2024

Kenneth K. Lee

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21104328

2 September 2024

A. James Moser

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21104328

2 September 2024

Herbert J. Zeh

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21104328

2 September 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21104328

2 September 2024

publication date

23 November 2010

1 reference

full work available at URL

23 August 2017

http://www.annalssurgicaloncology.org/cgi/content/abstract/18/4/1122

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21104328

http://link.springer.com/content/pdf/10.1245/s10434-010-1401-9.pdf

2 September 2024

file format

Portable Document Format

1 reference

https://api.crossref.org/works/10.1245/S10434-010-1401-9

http://link.springer.com/article/10.1245/s10434-010-1401-9/fulltext.html

2 September 2024

1 reference

https://api.crossref.org/works/10.1245/S10434-010-1401-9

http://link.springer.com/content/pdf/10.1245/s10434-010-1401-9

2 September 2024

1 reference

https://api.crossref.org/works/10.1245/S10434-010-1401-9

Annals of Surgical Oncology

2 September 2024

published in

1 reference

23 August 2017

1 reference

23 August 2017

1 reference

23 August 2017

page(s)

1122-1129

1 reference

Adjuvant 5-fluorouracil and folinic acid vs observation for pancreatic cancer: composite data from the ESPAC-1 and -3(v1) trials

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1245%2FS10434-010-1401-9

A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-010-1401-9

Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-010-1401-9

A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-010-1401-9

Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-010-1401-9

Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-010-1401-9

Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-010-1401-9

Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-010-1401-9

The ErbB signaling network: receptor heterodimerization in development and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-010-1401-9

ErbB-targeted therapeutic approaches in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-010-1401-9

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-010-1401-9

Clinicopathological predictors of EGFR/KRAS mutational status in primary lung adenocarcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-010-1401-9

Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-010-1401-9

Adjuvant interferon-based chemoradiation followed by gemcitabine for resected pancreatic adenocarcinoma: a single-institution phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-010-1401-9

Erlotinib 150 mg daily plus chemotherapy in advanced pancreatic cancer: an interim safety analysis of a multicenter, randomized, cross-over phase III trial of the 'Arbeitsgemeinschaft Internistische Onkologie'.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-010-1401-9

Epidermal growth factor receptor-targeted therapy for pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-010-1401-9

Erlotinib in lung cancer - molecular and clinical predictors of outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-010-1401-9

Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-010-1401-9

Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-010-1401-9

KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-010-1401-9

Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-010-1401-9

Validation of a prediction rule to maximize curative (R0) resection of early-stage pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-010-1401-9

Patterns of recurrence after curative resection of pancreatic ductal adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1245/S10434-010-1401-9

1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience

2 September 2024

1 reference

https://api.crossref.org/works/10.1245/S10434-010-1401-9

Gastrointestinal cancer research : GCR

2 September 2024

134

JF Sun

2009

1 reference

https://api.crossref.org/works/10.1245/S10434-010-1401-9

Classification of R1 resections for pancreatic cancer: the prognostic relevance of tumour involvement within 1 mm of a resection margin

2 September 2024

1 reference

https://api.crossref.org/works/10.1245/S10434-010-1401-9

2 September 2024

Identifiers

1 reference

Dimensions Publication ID

23 August 2017

1044061716

0 references

1 reference